Literature DB >> 12009780

Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease.

A Petersén1, K Chase, Z Puschban, M DiFiglia, P Brundin, N Aronin.   

Abstract

A transgenic mouse model of Huntington's disease (R6/1 and R6/2 lines) expressing exon 1 of the HD gene with 115-150 CAG repeats resisted striatal damage following injection of quinolinic acid and other neurotoxins. We examined whether excitotoxin resistance characterizes mice with mutant huntingtin transgenes. In a new transgenic mouse with 3 kb of mutant human huntingtin cDNA with 18, 46, or 100 CAG repeats, we found no change in susceptibility to intrastriatal injections of the excitotoxin quinolinic acid, compared to wild-type littermates. The new transgenic mice were injected with the same dose of quinolinic acid (30 nmol) as had been the R6 mice. Our findings highlight the importance of studying pathogenetic mechanisms in different transgenic models of a disease. Copyright 2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12009780     DOI: 10.1006/exnr.2002.7885

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  13 in total

Review 1.  Brain networks in Huntington disease.

Authors:  David Eidelberg; D James Surmeier
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

2.  Age-Dependent Resistance to Excitotoxicity in Htt CAG140 Mice and the Effect of Strain Background.

Authors:  Melissa K Strong; Amber L Southwell; Jennifer M Yonan; Michael R Hayden; Grant R Macgregor; Leslie M Thompson; Oswald Steward
Journal:  J Huntingtons Dis       Date:  2012

Review 3.  Huntington's disease: can mice lead the way to treatment?

Authors:  Zachary R Crook; David Housman
Journal:  Neuron       Date:  2011-02-10       Impact factor: 17.173

4.  Striatal Protection in nNOS Knock-Out Mice After Quinolinic Acid-Induced Oxidative Damage.

Authors:  C Gerónimo-Olvera; L Tristán-López; J C Martínez-Lazcano; L García-Lara; A Sánchez-Mendoza; A Morales-Martínez; M A Hernández-Melesio; L Arregui; C Ríos; F Pérez-Severiano
Journal:  Neurochem Res       Date:  2018-12-06       Impact factor: 3.996

Review 5.  Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.

Authors:  L A Raymond; V M André; C Cepeda; C M Gladding; A J Milnerwood; M S Levine
Journal:  Neuroscience       Date:  2011-08-27       Impact factor: 3.590

6.  Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease.

Authors:  Carlos Cepeda; Raymond S Hurst; Christopher R Calvert; Elizabeth Hernández-Echeagaray; Oanh K Nguyen; Emily Jocoy; Lindsey J Christian; Marjorie A Ariano; Michael S Levine
Journal:  J Neurosci       Date:  2003-02-01       Impact factor: 6.167

Review 7.  Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms.

Authors:  Carlos Cepeda; Damian M Cummings; Véronique M André; Sandra M Holley; Michael S Levine
Journal:  ASN Neuro       Date:  2010-04-07       Impact factor: 4.146

8.  Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease.

Authors:  Rona K Graham; Mahmoud A Pouladi; Prasad Joshi; Ge Lu; Yu Deng; Nan-Ping Wu; Bryan E Figueroa; Martina Metzler; Véronique M André; Elizabeth J Slow; Lynn Raymond; Robert Friedlander; Michael S Levine; Blair R Leavitt; Michael R Hayden
Journal:  J Neurosci       Date:  2009-02-18       Impact factor: 6.167

9.  Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.

Authors:  Hua Zhang; Qin Li; Rona K Graham; Elizabeth Slow; Michael R Hayden; Ilya Bezprozvanny
Journal:  Neurobiol Dis       Date:  2008-04-16       Impact factor: 5.996

Review 10.  Mouse models of Huntington's disease and methodological considerations for therapeutic trials.

Authors:  Robert J Ferrante
Journal:  Biochim Biophys Acta       Date:  2009-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.